USD 279.3
(0.54%)
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2023 | 377.36 Million USD | 1.43% |
2022 | 372.02 Million USD | 28.14% |
2021 | 290.32 Million USD | 56.77% |
2020 | 185.19 Million USD | 2.72% |
2019 | 180.28 Million USD | 94.71% |
2018 | 92.59 Million USD | 21.42% |
2017 | 76.25 Million USD | 82.84% |
2016 | 41.7 Million USD | 33.14% |
2015 | 31.32 Million USD | -76.58% |
2014 | 133.75 Million USD | 68.86% |
2013 | 79.2 Million USD | 0.0% |
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2024 Q2 | 373.33 Million USD | -0.79% |
2024 Q3 | 374.84 Million USD | 0.41% |
2024 Q1 | 376.31 Million USD | -0.28% |
2023 Q4 | 377.36 Million USD | 3.6% |
2023 Q2 | 365.98 Million USD | -1.31% |
2023 Q3 | 364.23 Million USD | -0.48% |
2023 Q1 | 370.82 Million USD | -0.32% |
2023 FY | 377.36 Million USD | 1.43% |
2022 Q2 | 357.88 Million USD | 4.56% |
2022 FY | 372.02 Million USD | 28.14% |
2022 Q3 | 347.84 Million USD | -2.8% |
2022 Q4 | 372.02 Million USD | 6.95% |
2022 Q1 | 342.27 Million USD | 17.89% |
2021 Q2 | 236.84 Million USD | 24.42% |
2021 Q1 | 190.35 Million USD | 2.79% |
2021 FY | 290.32 Million USD | 56.77% |
2021 Q3 | 288.63 Million USD | 21.87% |
2021 Q4 | 290.32 Million USD | 0.58% |
2020 Q4 | 185.19 Million USD | -2.83% |
2020 Q3 | 190.59 Million USD | 21.37% |
2020 FY | 185.19 Million USD | 2.72% |
2020 Q2 | 157.03 Million USD | -10.84% |
2020 Q1 | 176.12 Million USD | -2.31% |
2019 Q1 | 132.12 Million USD | 42.7% |
2019 Q4 | 180.28 Million USD | 22.45% |
2019 FY | 180.28 Million USD | 94.71% |
2019 Q2 | 130.92 Million USD | -0.91% |
2019 Q3 | 147.22 Million USD | 12.45% |
2018 FY | 92.59 Million USD | 21.42% |
2018 Q2 | 74.11 Million USD | -0.9% |
2018 Q1 | 74.78 Million USD | -1.93% |
2018 Q4 | 92.59 Million USD | 0.95% |
2018 Q3 | 91.71 Million USD | 23.75% |
2017 FY | 76.25 Million USD | 82.84% |
2017 Q1 | 44.89 Million USD | 7.64% |
2017 Q2 | 44.02 Million USD | -1.93% |
2017 Q3 | 75.26 Million USD | 70.95% |
2017 Q4 | 76.25 Million USD | 1.32% |
2016 FY | 41.7 Million USD | 33.14% |
2016 Q1 | 37.07 Million USD | 18.35% |
2016 Q2 | 36.38 Million USD | -1.85% |
2016 Q3 | 43.42 Million USD | 19.34% |
2016 Q4 | 41.7 Million USD | -3.96% |
2015 Q3 | 30.73 Million USD | 7.08% |
2015 Q1 | 24.36 Million USD | -81.78% |
2015 FY | 31.32 Million USD | -76.58% |
2015 Q4 | 31.32 Million USD | 1.92% |
2015 Q2 | 28.7 Million USD | 17.8% |
2014 Q4 | 133.75 Million USD | 0.0% |
2014 FY | 133.75 Million USD | 68.86% |
2013 FY | 79.2 Million USD | 0.0% |
Name | Total Liabilities | Total Liabilities Difference |
---|---|---|
Abbott Laboratories | 34.38 Billion USD | 98.903% |
Allurion Technologies Inc. | 142.19 Million USD | -165.375% |
Artivion, Inc. | 510.61 Million USD | 26.097% |
Avanos Medical, Inc. | 456.1 Million USD | 17.264% |
Butterfly Network, Inc. | 84.22 Million USD | -348.06% |
Butterfly Network, Inc. | 84.22 Million USD | -348.06% |
Bio-Rad Laboratories, Inc. | 3.55 Billion USD | 89.394% |
Boston Scientific Corporation | 15.6 Billion USD | 97.582% |
CONMED Corporation | 1.46 Billion USD | 74.256% |
Edwards Lifesciences Corporation | 2.64 Billion USD | 85.727% |
Paragon 28, Inc. | 162.95 Million USD | -131.569% |
Glaukos Corporation | 478.64 Million USD | 21.161% |
Globus Medical, Inc. | 1.08 Billion USD | 65.32% |
Inspire Medical Systems, Inc. | 104.29 Million USD | -261.814% |
Integer Holdings Corporation | 1.41 Billion USD | 73.298% |
Medtronic plc | 39.56 Billion USD | 99.046% |
Myomo, Inc. | 5.59 Million USD | -6647.967% |
Nevro Corp. | 330.31 Million USD | -14.244% |
Owlet, Inc. | 73.79 Million USD | -411.336% |
Vicarious Surgical Inc. | 21.89 Million USD | -1623.503% |
Smith & Nephew plc | 4.77 Billion USD | 92.089% |
Sonendo, Inc. | 49.74 Million USD | -658.652% |
STERIS plc | 4.74 Billion USD | 92.053% |
Stryker Corporation | 21.31 Billion USD | 98.23% |
Vapotherm, Inc. | 132.95 Million USD | -183.835% |
Zimmer Biomet Holdings, Inc. | 9 Billion USD | 95.811% |